Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4

Inactive Publication Date: 2006-11-23
KING'S COLLEGE LONDON +1
View PDF4 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006] The invention provides a method of treating an inflammatory condition in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a lymphoid thymosin-β4 polyp

Problems solved by technology

Inflammatory conditions are a significant cause of disabilities that acco

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
  • Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
  • Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of pTβ4 Splice-Variants by Vγ5+ DETC

[0146] Situated within numerous epithelia of rodents and many other vertebrates are intraepithelial lymphocytes (IELs) composed predominantly of T cells and frequently enriched in those expressing heterodimeric γδ T cell receptors (TCR) [reviewed in 1]. IELs would seem ideally located to maintain epithelial integrity in the face of environmental insults, and it was recently shown that γδ cell deficient mice are highly susceptible to chemically-induced squamous cell carcinomas that can in vitro be directly targeted for cytolysis by cutaneous IELs, specifically Vγ5+ dendritic epidermal T cells (DETC) [reference 2].

[0147] While DETC can kill dysregulated epithelial cells, they have also been reported to synthesise fibroblast growth factors that may promote epidermal wound healing [reference 3]. Consistent with a role for cutaneous IELs in maintaining epidermal integrity, is the observation that the skin of FVB or NOD mice lacking DETC be...

example 2

Synthesis of Thymosins for Bioassay

[0153] Available evidence indicates that the major fraction of UTβ4 undergoes N-terminal methionine processing [references 8, 12], but the known rules for aminopeptidase activity [reference 15] do not permit one to make the same assumption for LTβ4. Therefore, in our experiments to determine the biological activities of UTβ4 and LTβ4, we synthesised both N-terminal methionated and un-methionated forms of each polypeptide. The four peptides (UTβ4; methionated-UTβ4 (“mUTβ4”), LT4; and methionated-LTβ4 (“mLTβ4”)) were synthesized by CS Bio Co. (San Diego, Calif.), using peptide coupling chemistry, and purified (>98%) by reverse phase HPLC (high performance liquid chromatography). The amino acid sequences were as follows: UTβ4: N-SDKPDMAEIEKFDKSKLKKTETQEKNPL-PSKETIEQEKQAGES-C (SEQ ID NO:1); mUTβ4: N-MSDKPDMAEIEKFDKSKLKKTETQEKNPL-PSKETIEQEKQAGES-C (SEQ ID NO:2); LTβ4: N-LLPATMSDKPDMAEIEKFDKSKLKKTE-TQEKNPLPSKETIEQEKQAGES-C (SEQ ID NO:8); and mLTβ4: N-ML...

example 3

Activities of UTβ4 and LTβ4 in λ-Carrageenan-Induced Inflammation

[0161] Prior to this invention, no one had evaluated the effects of LTβ4 on neutrophil mediated inflammation. Neutrophils mediate many inflammatory reactions found in skin diseases, including neutrophilic dermatoses, pustular eruptions in systemic diseases, and neutrophilic drug eruptions. In his 2000 review article of neutrophilic dermatoses (ND), Wallach presents a classification of neutrophil mediated dermatoses including Sweet's Syndrome, Pyoderma Gangrenosum, Subcorneal Pustular Dermatosis and Erythema Elevatum Diutinum (Wallach, D (2000) Neutrophilic Dermatoses: An Overview. Clinics in Dermatology 18:229-231). In Callen's review of “Pustual Eruptions in Systemic Disease,” neutrophils were identified in playing a role in skin manifestations of Ulcerative Colitis, Rheumatoid Arthritis, and Bechet's Disease (Callen, (2000) Pustular Eruptions in Systemic Disease. Clinics in Dermatology 18:349-353). Finally, in Rouje...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of the filing date of U.S. Provisional Application No. 60 / 372,614 filed Apr. 12, 2002 and entitled “Lymphoid Thymosin Beta 4 (LTB4) As An Anti-Inflammatory and Wound Healing Therapy,” by Michael Girardi, Adrian C. Hayday, Michael A. Sherling, John Shires, Efstathios Theodoridis, and Robert E. Tigelaar. The entire teachings of the referenced provisional application are incorporated herein by reference.GOVERNMENT SUPPORT [0002] The invention described herein was supported, in whole or in part, by Grant No. KO8AR02072 from the National Institute of Health. The United States Government has certain rights in this invention.BACKGROUND OF THE INVENTION [0003] Inflammatory conditions are a significant cause of disabilities that accompany a variety of disease. Inflammatory conditions includes, but are not limited to, a conditions of the skin, lungs, and gut. Inflammatory conditions are currently treated with a diversity of agent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/22C07K14/575
CPCA61K38/00C07K14/57581A61P19/02
Inventor GIRARDI, MICHAELTIGELAAR, ROBERTSHERLING, MICHAELSHIRES, JOHNHAYDAY, ADRIANTHEODORIDIS, EFATATHIOS
Owner KING'S COLLEGE LONDON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap